AveXis, Inc. (NASDAQ:AVXS) – Stock analysts at Jefferies Group issued their Q3 2018 EPS estimates for AveXis in a research report issued on Thursday. Jefferies Group analyst B. Amin expects that the company will earn ($1.58) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $118.00 price objective on the stock. Jefferies Group also issued estimates for AveXis’ Q4 2018 earnings at ($0.96) EPS.

A number of other research firms have also recently issued reports on AVXS. BMO Capital Markets reissued a “buy” rating and issued a $123.00 price target on shares of AveXis in a research note on Friday, August 11th. Bank of America Corporation lowered their target price on shares of AveXis from $115.00 to $112.00 and set a “buy” rating on the stock in a research note on Friday. Morgan Stanley reaffirmed an “overweight” rating and set a $118.00 target price on shares of AveXis in a research note on Wednesday, August 9th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $134.00 target price (up previously from $89.00) on shares of AveXis in a research note on Tuesday, September 5th. Finally, Evercore ISI initiated coverage on shares of AveXis in a research note on Wednesday, August 16th. They set an “outperform” rating and a $120.00 target price on the stock. Two research analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $108.26.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/11/13/avexis-inc-avxs-forecasted-to-post-q3-2018-earnings-of-1-58-per-share.html.

Shares of AveXis (AVXS) opened at $95.79 on Monday. AveXis has a one year low of $44.68 and a one year high of $108.27.

AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.04). During the same quarter in the previous year, the business earned ($0.87) EPS.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. raised its holdings in AveXis by 25.4% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 108,513 shares of the company’s stock valued at $10,497,000 after buying an additional 21,993 shares during the period. Wells Fargo & Company MN raised its holdings in AveXis by 59.6% in the 3rd quarter. Wells Fargo & Company MN now owns 26,170 shares of the company’s stock valued at $2,531,000 after buying an additional 9,769 shares during the period. Amalgamated Bank raised its holdings in AveXis by 19.6% in the 3rd quarter. Amalgamated Bank now owns 3,187 shares of the company’s stock valued at $308,000 after buying an additional 523 shares during the period. Legal & General Group Plc raised its holdings in AveXis by 76.4% in the 3rd quarter. Legal & General Group Plc now owns 10,283 shares of the company’s stock valued at $1,000,000 after buying an additional 4,455 shares during the period. Finally, Eagle Asset Management Inc. raised its holdings in AveXis by 41.9% in the 3rd quarter. Eagle Asset Management Inc. now owns 158,528 shares of the company’s stock valued at $15,180,000 after buying an additional 46,835 shares during the period. Hedge funds and other institutional investors own 94.96% of the company’s stock.

In other news, VP Sukumar Nagendran sold 1,780 shares of AveXis stock in a transaction on Friday, September 1st. The stock was sold at an average price of $93.25, for a total transaction of $165,985.00. Following the transaction, the vice president now owns 1,780 shares in the company, valued at approximately $165,985. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Brian K. Kaspar sold 15,000 shares of AveXis stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $101.23, for a total value of $1,518,450.00. Following the transaction, the insider now owns 1,841,019 shares in the company, valued at approximately $186,366,353.37. The disclosure for this sale can be found here. In the last quarter, insiders have sold 35,340 shares of company stock worth $3,559,683. Insiders own 18.60% of the company’s stock.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Earnings History and Estimates for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.